Enveric Biosciences, Inc.

ENVB

US29405E2081

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
0.938 ^USD	+6.35%		+3.04%	-27.85%

Mar. 26	Enveric Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 19	Sector Update: Health Care Stocks Rise Late Afternoon	MT

AMERI : Financial Statements and Exhibits (form 8-K/A)

November 26, 2019 at 08:04 am EST

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits



  5.1   Opinion of Sheppard, Mullin, Richter & Hampton LLP



  10.1*   Form of Securities Purchase Agreement



  10.2*   Form of Convertible Debenture

*Filed with the Original 8-K.

-2-

--------------------------------------------------------------------------------

Latest news about Enveric Biosciences, Inc.

Enveric Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Sector Update: Health Care Stocks Rise Late Afternoon	Mar. 19	MT
Sector Update: Health Care Stocks Higher in Tuesday Afternoon Trading	Mar. 19	MT
Enveric Biosciences Signs Licensing Term Sheets for Joint Disease Treatment Compounds; Shares Rise	Mar. 19	MT
Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected	Mar. 19	MT
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease	Mar. 19	CI
Enveric Biosciences Issues 228,690 Shares in Direct Offering	Mar. 11	MT
Top Midday Gainers	Feb. 29	MT
Wall Street Set to Open Higher Thursday as Inflation Data Meets Forecasts	Feb. 29	MT
Investors Await Slate of Economic Data as US Futures Move Lower in Thursday's Premarket Session	Feb. 29	MT
Sector Update: Health Care Stocks Rise in Late Afternoon	Feb. 23	MT
Sector Update: Health Care Stocks Advance Friday Afternoon	Feb. 23	MT
Enveric Biosciences Surging on Plans to Sell Cannabinoid IP Portfolio, Focus Shift to Psilocin Therapies	Feb. 23	MT
Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders	Feb. 21	CI
HC Wainwright Initiates Enveric Biosciences With Buy Rating, Price Target is $10	Jan. 30	MT
Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series	Jan. 03	CI
Enveric Bioscience Generates $1.8 Million as Investors Exercise Warrants	Dec. 29	MT
Sector Update: Health Care Stocks Rise in Late Afternoon	Dec. 28	MT
Health Care Up on Defensive Bias -- Health Care Roundup	Dec. 28	DJ
Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series	Dec. 28	CI
Enveric Biosciences Selects EB-003 as Lead Drug Candidate to Treat Mental Health Disorders	Dec. 28	MT
Enveric Biosciences Selects Development Candidates from Evm301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds	Dec. 05	CI
Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry	Nov. 27	CI
Enveric Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373	23-10-18	CI

Chart Enveric Biosciences, Inc.

Duration

Period

More charts

Enveric Biosciences, Inc. is a biotechnology company. The Company is engaged in the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety and addiction disorders. The Company, through Psybrary has created a robust intellectual property (IP) portfolio of new chemical entities for specific mental health indications. Its lead program, the EVM201 Series, comprises synthetic prodrugs of the active metabolite, psilocin. It is developing the first product from the EVM201 Series, EB-002, for the treatment of psychiatric disorders. The Company is also advancing its second program, the EVM301 Series, EB 003, which is an approach to the treatment of difficult-to-address mental health disorders. Within the Psybrary, it has three different types of molecules, Generation 1 (classic psychedelics), Generation 2 (pro-drugs), and Generation 3 (new chemical entities). It has created over 1,000 novel psychedelic molecular compounds and derivatives.

Sector

Biotechnology & Medical Research

Calendar

2024-05-13 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.938 USD

Average target price

9 USD

Spread / Average Target

+859.49%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ENVERIC BIOSCIENCES, INC.	-27.85%	6.84M
IQVIA HOLDINGS INC.	-1.82%	41.35B
LONZA GROUP AG	+44.25%	40.38B
MODERNA, INC.	+2.56%	39.05B
CELLTRION, INC.	-12.11%	26.67B
ICON PUBLIC LIMITED COMPANY	+3.09%	24.07B
ALNYLAM PHARMACEUTICALS, INC.	-24.16%	18.36B
MEDPACE HOLDINGS, INC.	+22.12%	11.6B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.74%	11.68B
UNITED THERAPEUTICS CORPORATION	+7.75%	11.15B

Other Biotechnology & Medical Research

Enveric Biosciences, Inc.

Equities

ENVB

US29405E2081

Biotechnology & Medical Research

AMERI : Financial Statements and Exhibits (form 8-K/A)

Latest news about Enveric Biosciences, Inc.

Chart Enveric Biosciences, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research